CNS Disease

Questions discussed in this category

Is it safe to give large fraction stereotactic irradiation for brain metastases concurrently with VEGF inhibitors?

1 Answer available

Would you use T-DXd or capecitabine/trastuzumab/tucatinib for HER2+ metastatic breast cancer with predominantly CNS progression after THP?

Which regimen is preferred in second line for these patients? What is the efficacy of TDXd vs tucatinib in CNS metastases?

3 Answers available

Would you recommend adjuvant radiotherapy for recurrent paraganglioma with lymph node involvement treated with salvage neck dissection with no residual disease?

Would the rate of growth, number of nodes involved, size of nodes, ENE etc. affect your decision? What volume and dose would you recommend?

1 Answer available

What features or presentations would prompt you to offer radiotherapy for paraganglioma vs. continued surveillance?

Aside from symptomatic disease, is there a certain growth cutoff or other criteria that would be a trigger for treatment?

1 Answer available

Are there any circumstances in which you would recommend adjuvant chemoradiation for resected olfactory neuroblastoma?

4 Answers available

How do you approach the treatment of de novo, brain only metastatic HER2 positive breast cancer?

1 Answer available

Are there any features that help differentiate Sjogren's-related CNS demyelinating plaques from multiple sclerosis in a patient with primary Sjogren's syndrome?

1 Answer available

Papers discussed in this category

Multiple sclerosis (Houndmills, Basingstoke, England), 2014-01

Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome.

Ann. Neurol., 2018 Feb 15

Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.

N. Engl. J. Med., 2019 Dec 11

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

J Clin Oncol, 2020 May 29

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

N Engl J Med,

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

N Engl J Med, 2019 Dec 11

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2011 Jun 15

Esthesioneuroblastoma: is there a need for elective neck treatment?

Cancer, 2004-12-01

Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Related Topics